TIMELINE FOR THE IMPLEMENTATION OF EO 14273: LOWERING DRUG PRICES BY ONCE AGAIN PUTTING AMERICANS FIRST

CURRENT AS OF AUGUST 6, 2025

SEC. 3: Improving upon the Inflation Reduction Act — Release Medicare Drug Price Negotiation Program Guidance for IPAY 2028 and MFP effectuation for IPAY 2026-2028

SEC. 10: Increasing Prescription Drug Importation to Lower Prices — Steps to increase importation

SEC. 4: Reducing the Prices of High-Cost Drugs for Seniors — Rulemaking for a CMMI drug pricing model. Most recently, it was announced that rulemaking may occur if voluntary progress towards Most Favored Nation Pricing is not made.

SEC. 7: Access to Affordable Life-Saving Medications — Requiring low-income individuals in community health centers have access to insulin and injectable epinephrine at or below 340B acquisition cost

SEC. 11: Reducing Costly Care for Seniors — Propose regulations on site neutrality between hospital outpatient departments and physician offices

SEC. 5: Appropriately Accounting for Acquisition Costs of Drugs in Medicare — Publish plan for conducting a survey to determine hospital acquisition cost for covered outpatient drugs

SEC. 3: Improving upon the Inflation Reduction Act — Recommendations on how to stabilize and reduce Medicare Part D premiums

SEC. 8: Reevaluating the Role of Middlemen
No recommendations have been publicly released

SEC. 13. Combating Anti-Competitive Behavior by Prescription Drug Manufacturers — Joint listening sessions (completed) and report on combating anti-competitive manufacturer behavior (pending)

MAY | JUNE | JULY | AUGUST | SEPTEMBER | OCTOBER

- Completed on or ahead of schedule
- Pending
- Pending with deadline of 10/12/25
- Missed deadline
- No timeline specified

SEC. 9: Accelerating Competition for High-Cost Prescription Drugs — Report with recommendations on accelerating access to generics, biosimilars, combination products, second-in-class brand name medications, and OTC medications

SEC. 12: Improving Transparency into Pharmacy Benefit Manager Fee Disclosure — Propose regulations related to fiduciary transparency requirements under Employee Retirement Income Security Act (ERISA) of 1974

SEC. 6. Promoting Innovation, Value, and Enhanced Oversight in Medicaid Drug Payment — Recommendations on Medicaid drug pricing reforms

SEC. 3: Improving upon the Inflation Reduction Act — Addressing “pill penalty”

ACCESS A FULL OVERVIEW **HERE**

APPLIED POLICY®